The Pharma Data

NOVEMBER 9, 2020

Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Sites of care will then confirm their need and AmerisourceBergen will distribute bamlanivimab overnight.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52

The Pharma Data

JANUARY 26, 2021

While the preliminary nature of Phase 2 results from COVID-19 neutralizing monoclonal antibodies may have limited acceptance of treatment, these Phase 3 data further strengthen the available evidence,” said Daniel Skovronsky, M.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

DECEMBER 10, 2020

First in line are health care personnel and residents and staff of long-term care facilities, according to earlier recommendations released by the CDC panel. Doctors say this reflects India’s younger and leaner population.

Vaccine 52

Vaccine FDA Long-Term Care Facilities Hospitals 52

The Pharma Data

DECEMBER 17, 2020

Regardless of their decisions or which treatment they receive, all participants will be monitored for two years. Currently, healthcare personnel and long-term care facility residents participating in their trial are the only ones who can opt to receive the vaccine.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52